139 related articles for article (PubMed ID: 38227617)
1. Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations.
Thaman P; Kulig CE; Greer D
J Clin Psychopharmacol; 2024 Mar-Apr 01; 44(2):96-99. PubMed ID: 38227617
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
[TBL] [Abstract][Full Text] [Related]
3. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
Maestri TJ; Mican LM; Rozea H; Barner JC
Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
[TBL] [Abstract][Full Text] [Related]
4. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
5. Assessing the impact of long-acting injectable compared to oral antipsychotic medications on readmission to a state psychiatric hospital.
Okoli CTC; Abufarsakh B; Wang T; Makowski A; Cooley A
J Psychiatr Ment Health Nurs; 2024 Jun; ():. PubMed ID: 38922793
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of long-acting injectable antipsychotics to reduce 90-day and annual readmission in psychotic disorders: insights from a state psychiatric hospital.
Patel RS; Tankersley WE
CNS Spectr; 2022 Oct; 27(5):626-633. PubMed ID: 33938426
[TBL] [Abstract][Full Text] [Related]
7. Identifying Predictors of Primary Adherence to Second Generation Long-Acting Injectable Antipsychotics Following Discharge from an Acute Inpatient Psychiatry Unit.
Gilbert JL; Nelson LA; Kriz CR; Liu Y; Iuppa CA; Diefenderfer LA; Elliott ESR; Sommi RW
Psychopharmacol Bull; 2019 Jun; 49(2):8-16. PubMed ID: 31308578
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.
Aggarwal NK; Sernyak MJ; Rosenheck RA
J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006
[TBL] [Abstract][Full Text] [Related]
9. Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia.
Tidmore LM; Keast SL; Waters HC; Pareja KL; Cothran T; Skrepnek GH
Curr Med Res Opin; 2022 Sep; 38(9):1621-1630. PubMed ID: 35833696
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics.
Shah A; Xie L; Kariburyo F; Zhang Q; Gore M
Adv Ther; 2018 Nov; 35(11):1994-2014. PubMed ID: 30269292
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics.
Kheloussi S; Oberlin J; Trauger M; Testa ND
J Manag Care Spec Pharm; 2022 Oct; 28(10):1130-1137. PubMed ID: 36125056
[No Abstract] [Full Text] [Related]
12. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
[TBL] [Abstract][Full Text] [Related]
13. Combination Psychotropic Use for Schizophrenia With Long-Acting Injectable Antipsychotics and Oral Antipsychotics: A Nationwide Real-World Study in Japan.
Onitsuka T; Okada T; Hasegawa N; Tsuboi T; Iga JI; Yasui-Furukori N; Yamada N; Hori H; Muraoka H; Ohi K; Ogasawara K; Ochi S; Takeshima M; Ichihashi K; Fukumoto K; Iida H; Yamada H; Furihata R; Makinodan M; Takaesu Y; Numata S; Komatsu H; Hishimoto A; Kido M; Atake K; Yamagata H; Kikuchi S; Hashimoto N; Usami M; Katsumoto E; Asami T; Kubota C; Matsumoto J; Miura K; Hirano Y; Watanabe K; Inada K; Hashimoto R
J Clin Psychopharmacol; 2023 Jul-Aug 01; 43(4):365-368. PubMed ID: 37216369
[TBL] [Abstract][Full Text] [Related]
14. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
15. Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics.
MacEwan JP; Kamat SA; Duffy RA; Seabury S; Chou JW; Legacy SN; Hartry A; Eramo A; Karson C
Psychiatr Serv; 2016 Nov; 67(11):1183-1188. PubMed ID: 27417897
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
17. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
19. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.
Buckley PF; Schooler NR; Goff DC; Hsiao J; Kopelowicz A; Lauriello J; Manschreck T; Mendelowitz AJ; Miller del D; Severe JB; Wilson DR; Ames D; Bustillo J; Mintz J; Kane JM;
Schizophr Bull; 2015 Mar; 41(2):449-59. PubMed ID: 24870446
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
